Core Insights - Cardinal Health reported $60.16 billion in revenue for the quarter ended June 2025, a year-over-year increase of 0.5% and an EPS of $2.08 compared to $1.84 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $60.67 billion, resulting in a surprise of -0.84%, while the EPS exceeded the consensus estimate of $2.03 by +2.46% [1] Revenue Breakdown - Pharmaceutical and Specialty Solutions revenue was $55.37 billion, slightly below the average estimate of $55.86 billion, reflecting a year-over-year decline of -0.4% [4] - Corporate revenue reported at -$21 million, better than the estimated -$21.65 million, but a significant year-over-year decrease of -12.5% [4] - Other revenue reached $1.61 billion, surpassing the average estimate of $1.57 billion, marking a substantial year-over-year increase of +37.3% [4] - Medical Products and Distribution revenue was $3.2 billion, in line with the average estimate of $3.21 billion, showing a year-over-year growth of +2.9% [4] Segment Profit Analysis - Segment profit for Pharmaceutical and Specialty Solutions was $535 million, slightly below the average estimate of $543.86 million [4] - Segment profit for Other was $160 million, exceeding the average estimate of $147.91 million [4] - Global Medical Products and Distribution segment profit was $70 million, above the average estimate of $65.48 million [4] Stock Performance - Cardinal Health's shares have returned -2.5% over the past month, contrasting with the Zacks S&P 500 composite's +2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Q3 FY25 Earnings Cardinal Health, Inc. May 1, 2025 © 2025 Cardinal Health. All Rights Reserved. 1 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings Cautions Concerning Forward-Looking Statements Q3 Results © 2025 Cardinal Health. All Rights Reserved. 3 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These st ...

Group 1 - The upcoming report from Cardinal Health (CAH) is expected to show quarterly earnings of $2.15 per share, reflecting a 3.4% increase year-over-year [1] - Analysts forecast revenues of $55.03 billion for the quarter, indicating a 0.2% increase compared to the previous year [1] - The consensus EPS estimate has been revised 0.1% lower over the last 30 days, indicating a reevaluation of initial estimates by analysts [1][2] Group 2 - Analysts estimate that 'Revenue- Pharmaceutical and Specialty Solutions' will reach $50.33 billion, representing a -0.6% change from the year-ago quarter [4] - The 'Revenue- Medical Products and Distribution' is projected to be $3.21 billion, indicating a year-over-year increase of 3.2% [4] - Segment profit for 'Pharmaceutical and Specialty Solutions' is forecasted to be $635.77 million, up from $580 million in the same quarter last year [5] Group 3 - The 'Segment profit- Global Medical Products and Distribution' is expected to reach $44.16 million, compared to $20 million in the previous year [5] - Over the past month, Cardinal shares have recorded returns of +0.8%, while the Zacks S&P 500 composite has seen a -4.3% change [5] - Cardinal Health holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [5]